2024-11-10 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc, commonly known as Merck, is a global pharmaceutical and healthcare company that develops, manufactures, and markets a wide range of prescription drugs, vaccines, and animal health products. 

**Performance Analysis:**

**1. Performance vs. S&P 500:**

* **Cumulative Return:** MRK: 56.92%, VOO (S&P 500): 141.71%
* **Performance Gap:** -84.79% (relative to VOO)
* **Relative Performance:** MRK has significantly underperformed the S&P 500 in the past period. This is further indicated by the relative performance of 1.84 which suggests MRK's performance is lower than 84% of the historical data.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|-------|
| 2015-2017 | -1.6% | 18.1% | -31.8% | 0.9 |
| 2016-2018 | 45.6% | 17.0% | 20.9% | 0.7 |
| 2017-2019 | 51.2% | 17.0% | 8.1% | 0.7 |
| 2018-2020 | 45.5% | 27.2% | 6.4% | 0.7 |
| 2019-2021 | 6.3% | 27.2% | -83.6% | 0.6 |
| 2020-2022 | 26.3% | 27.2% | 8.6% | 0.5 |
| 2021-2023 | 41.1% | 19.8% | 12.3% | 0.3 |
| 2022-2024 | 31.6% | 23.2% | 7.0% | 0.3 |

* **CAGR:** MRK's performance varies across different time frames, showcasing periods of strong returns and underperformance.
* **Alpha:**  Positive alpha indicates outperformance compared to the benchmark, while negative alpha suggests underperformance. MRK has shown periods of both outperformance and underperformance.
* **Beta:** Beta measures volatility relative to the market. MRK generally exhibits a beta less than 1, suggesting lower volatility than the market.

**2. Recent Price Action:**

* **Closing Price:** 101.17 
* **Last Market Price:** 102.97 (potential upward movement)
* **5-day Moving Average:** 101.46
* **20-day Moving Average:** 105.57
* **60-day Moving Average:** 111.79

* **Analysis:** The stock price is currently below all three moving averages, indicating a possible downtrend. The last market price at 102.97 suggests potential upward movement. 

**3. Technical Indicators:**

* **RSI:** 17.85 (Oversold)
* **PPO:** -0.23 (Weak momentum)
* **Delta_Previous_Relative_Divergence:** -18.58 (Short-term downtrend)
* **Expected Return:** 0.0% (Expected long-term return relative to S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

* **Analysis:** Recent earnings show a mixed picture with some fluctuations in EPS and revenue. 

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |

* **Analysis:** Merck consistently generates strong revenue and profitability. ROE has fluctuated but generally remains positive. 

**6. News and Recent Issues:**

* **Recent Earnings Releases:** 
    * Check for recent earnings releases on financial news websites like Bloomberg, Reuters, and Yahoo Finance. Look for key highlights, analyst reactions, and any notable developments. 
* **Market Outlook:**
    * Consult with FINBOLD or other reliable financial news sources to obtain recent market outlooks and analyst opinions on MRK's performance. 
    * Pay attention to factors like future growth opportunities, competitive landscape, and potential regulatory risks.

**7. Overall Analysis:**

* Merck is a large pharmaceutical company with a strong track record of profitability and revenue generation.
* Recent performance has been relatively subdued compared to the S&P 500, and technical indicators suggest a possible downtrend.
* Current price action is below moving averages, but a recent increase in the last market price indicates potential upward momentum.
* The company's expected return relative to the S&P 500 is 0.0%, suggesting long-term investors might not expect significant outperformance compared to the market.
* Monitor recent earnings releases and analyst opinions for key insights into the company's future direction.

**Conclusion:**

Merck & Co Inc (MRK) remains a solid company with a strong financial position. However, its recent underperformance and current technical indicators suggest a potential downtrend. While the company's expected long-term return is not expected to significantly outperform the market, its strong track record of profitability and revenue generation make it a potential consideration for investors with a long-term horizon. 

**Recommendation:** Investors should monitor the company's recent earnings releases and analyst opinions for further insight into the company's future direction. 
